<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03306121</url>
  </required_header>
  <id_info>
    <org_study_id>2017-FXY-034</org_study_id>
    <nct_id>NCT03306121</nct_id>
  </id_info>
  <brief_title>TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma</brief_title>
  <official_title>Phase Ⅲ Trial of Induction Chemotherapy（TPF） Followed by Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy (PF) in Patients With High Risk Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To see the effect of induction chemotherapy（TPF） followed by concurrent chemoradiotherapy&#xD;
      versus concurrent chemoradiotherapy followed by adjuvant chemotherapy (PF) in treating&#xD;
      patients with high risk nasopharyngeal carcinoma (NPC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients presented with non-keratinizing NPC and stage AnyTN2-3M0 and plasma EBV&#xD;
      DNA≥1500copies/ml are randomly assigned to receive TPF(paclitaxel&#xD;
      liposome+cisplatin+5-fluorouracil) induction chemotherapy plus concurrent chemoradiotherapy&#xD;
      (investigational arm) or concurrent chemoradiotherapy plus PF (cisplatin+5-fluorouracil)&#xD;
      adjuvant chemotherapy (control arm). Patients in both arms receive intensity-modulated&#xD;
      radiotherapy(IMRT), and cisplatin (100mg/m2) every three weeks for three cycles during&#xD;
      radiotherapy. Patients in the investigational arm receive paclitaxel liposome (135mg/m2 on&#xD;
      day 1), cisplatin (25mg/m2 on day 1-3) and 5-fluorouracil (750mg/m2 civ 120h) every three&#xD;
      weeks for three cycles before the radiotherapy. Patients in the control arm receive adjuvant&#xD;
      cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every four weeks for&#xD;
      three cycles after the radiotherapy. The primary end point is progress-free survival (PFS).&#xD;
      Secondary end points include overall survival(OS),locoregional failure-free survival(LRRFS),&#xD;
      distant metastasis-free survival(DMFS), overall response rates after treatments and toxic&#xD;
      effects(short-term and long-term). All efficacy analyses are conducted in the&#xD;
      intention-to-treat population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 13, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress-free survival(PFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Progress-free survival is calculated from the date of randomization to the date of the first progress at any site or death from any cause or censored at the date of the last follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>3 years</time_frame>
    <description>The OS was defined as the duration from the date of random assignment to the date of death from any cause or censored at the date of the last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional failure-free survival(LRRFS)</measure>
    <time_frame>3 years</time_frame>
    <description>The LRRFS is evaluated and calculated from the date of random assignment until the day of first locoregional relapse or until the date of the last follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis-free survival(DMFS)</measure>
    <time_frame>3 years</time_frame>
    <description>The DMFS is evaluated and calculated from the date of random assignment until the day of first distant metastases or until the date of the last follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>16 weeks after completion of IMRT</time_frame>
    <description>Tumour response was classified according to RECIST, version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute and late toxicity</measure>
    <time_frame>3 years</time_frame>
    <description>Incidence of acute toxicity is calculated for each adverse event respectively and severity is evaluated on basis of Common Terminology Criteria for Adverse Events (CTCAE) 4.0 criteria.Late radiation toxicities were assessed using the Radiation Therapy Oncology Group and European Organization for Research and Treatment of Cancer late radiation morbidity scoring scheme.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">322</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>TPF+CCRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive induction chemotherapy with paclitaxel liposome (135mg/m2 on day 1) ,cisplatin (25mg/m2 on day 1-3) and 5-fluorouracil (750mg/m2 civ 120h) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg/m2) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CCRT+ PF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive concurrent IMRT and cisplatin (100mg/m2) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) , then followed by three cycles of adjuvant chemotherapy with cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every four weeks for three cycles four weeks after radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPF+CCRT</intervention_name>
    <description>Patients receive paclitaxel liposome (135mg/m2 on day 1) , cisplatin (25mg/m2 on day 1-3) and 5-fluorouracil (750mg/m2 civ 120h) every three weeks for three cycles of induction chemotherapy before radiotherapy.&#xD;
Patients receive IMRT and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy (D1,D22,D43 of RT)</description>
    <arm_group_label>TPF+CCRT</arm_group_label>
    <other_name>TPF induction chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CCRT+ PF</intervention_name>
    <description>Patients receive cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every four weeks for three cycles 4 weeks after radiotherapy.&#xD;
Patients receive IMRT and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy (D1,D22,D43 of RT)</description>
    <arm_group_label>CCRT+ PF</arm_group_label>
    <other_name>Adjuvant PF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with newly histologically confirmed non-keratinizing carcinoma (according to&#xD;
             World Health Organization (WHO) histologically type).&#xD;
&#xD;
          -  Original clinical staged as anyT N2-3M0（according to the American Joint Committee on&#xD;
             Cancer(AJCC) 7th edition）and plasma EBVDNA≥1500copies/ml&#xD;
&#xD;
          -  No evidence of distant metastasis (M0).&#xD;
&#xD;
          -  Age 18-65 years old.&#xD;
&#xD;
          -  ECOG Performance status less or equal to 1&#xD;
&#xD;
          -  Adequate marrow: leucocyte count ≥4000/μL, hemoglobin ≥90g/L and platelet count&#xD;
             ≥100000/μL.&#xD;
&#xD;
          -  Normal liver function test: Alanine Aminotransferase (ALT)、Aspartate Aminotransferase&#xD;
             (AST) &lt;1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP)&#xD;
             ≤2.5×ULN, and bilirubin ≤ULN.&#xD;
&#xD;
          -  Adequate renal function: creatinine clearance ≥60 ml/min.&#xD;
&#xD;
          -  Patients must be informed of the investigational nature of this study and give written&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  WHO Type keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma.&#xD;
&#xD;
          -  Age &lt;18 or &gt;65years.&#xD;
&#xD;
          -  Treatment with palliative intent.&#xD;
&#xD;
          -  Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in&#xD;
             situ cervical cancer.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  History of previous radiotherapy (except for non-melanomatous skin cancers outside&#xD;
             intended RT treatment volume).&#xD;
&#xD;
          -  Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes.&#xD;
&#xD;
          -  Any severe intercurrent disease, which may bring unacceptable risk or affect the&#xD;
             compliance of the trial, for example, unstable cardiac disease requiring treatment,&#xD;
             renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose&#xD;
             &gt;1.5×ULN), and emotional disturbance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hai-Qiang Mai, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-sen Universitty Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Yat-sen Universitty Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998 Apr;16(4):1310-7. doi: 10.1200/JCO.1998.16.4.1310.</citation>
    <PMID>9552031</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee AW, Tung SY, Ngan RK, Chappell R, Chua DT, Lu TX, Siu L, Tan T, Chan LK, Ng WT, Leung TW, Fu YT, Au GK, Zhao C, O'Sullivan B, Tan EH, Lau WH. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials. Eur J Cancer. 2011 Mar;47(5):656-66. doi: 10.1016/j.ejca.2010.10.026. Epub 2010 Nov 26.</citation>
    <PMID>21112774</PMID>
  </results_reference>
  <results_reference>
    <citation>Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, Chan AT, Huang PY, Benhamou E, Zhu G, Chua DT, Chen Y, Mai HQ, Kwong DL, Cheah SL, Moon J, Tung Y, Chi KH, Fountzilas G, Zhang L, Hui EP, Lu TX, Bourhis J, Pignon JP; MAC-NPC Collaborative Group. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015 Jun;16(6):645-55. doi: 10.1016/S1470-2045(15)70126-9. Epub 2015 May 6.</citation>
    <PMID>25957714</PMID>
  </results_reference>
  <results_reference>
    <citation>Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, Chen XZ, Li JG, Zhu XD, Hu CS, Xu XY, Chen YY, Hu WH, Guo L, Mo HY, Chen L, Mao YP, Sun R, Ai P, Liang SB, Long GX, Zheng BM, Feng XL, Gong XC, Li L, Shen CY, Xu JY, Guo Y, Chen YM, Zhang F, Lin L, Tang LL, Liu MZ, Ma J. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016 Nov;17(11):1509-1520. doi: 10.1016/S1470-2045(16)30410-7. Epub 2016 Sep 27.</citation>
    <PMID>27686945</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen C, Wang FH, An X, Luo HY, Wang ZQ, Liang Y, Zhang L, Li YH. Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma. Cancer Chemother Pharmacol. 2013 Feb;71(2):371-8. doi: 10.1007/s00280-012-2020-x. Epub 2012 Nov 10.</citation>
    <PMID>23143190</PMID>
  </results_reference>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>October 1, 2017</study_first_submitted>
  <study_first_submitted_qc>October 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2017</study_first_posted>
  <last_update_submitted>May 19, 2023</last_update_submitted>
  <last_update_submitted_qc>May 19, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Hai-Qiang Mai,MD,PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Nasopharyngeal carcinoma;Induction chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03306121
org study id: 2017-FXY-034
nct id: NCT03306121
lead sponsor: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
To see the effect of induction chemotherapy（TPF） followed by concurrent chemoradiotherapy
      versus concurrent chemoradiotherapy followed by adjuvant chemotherapy (PF) in treating
      patients with high risk nasopharyngeal carcinoma (NPC).
Patients presented with non-keratinizing NPC and stage AnyTN2-3M0 and plasma EBV
      DNA≥1500copies/ml are randomly assigned to receive TPF(paclitaxel
      liposome+cisplatin+5-fluorouracil) induction chemotherapy plus concurrent chemoradiotherapy
      (investigational arm) or concurrent chemoradiotherapy plus PF (cisplatin+5-fluorouracil)
      adjuvant chemotherapy (control arm). Patients in both arms receive intensity-modulated
      radiotherapy(IMRT), and cisplatin (100mg/m2) every three weeks for three cycles during
      radiotherapy. Patients in the investigational arm receive paclitaxel liposome (135mg/m2 on
      day 1), cisplatin (25mg/m2 on day 1-3) and 5-fluorouracil (750mg/m2 civ 120h) every three
      weeks for three cycles before the radiotherapy. Patients in the control arm receive adjuvant
      cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every four weeks for
      three cycles after the radiotherapy. The primary end point is progress-free survival (PFS).
      Secondary end points include overall survival(OS),locoregional failure-free survival(LRRFS),
      distant metastasis-free survival(DMFS), overall response rates after treatments and toxic
      effects(short-term and long-term). All efficacy analyses are conducted in the
      intention-to-treat population.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Progress-free survival(PFS)
time frame: 3 years
description: Progress-free survival is calculated from the date of randomization to the date of the first progress at any site or death from any cause or censored at the date of the last follow-up.
measure: Overall survival(OS)
time frame: 3 years
description: The OS was defined as the duration from the date of random assignment to the date of death from any cause or censored at the date of the last follow-up.
measure: Locoregional failure-free survival(LRRFS)
time frame: 3 years
description: The LRRFS is evaluated and calculated from the date of random assignment until the day of first locoregional relapse or until the date of the last follow-up visit.
measure: Distant metastasis-free survival(DMFS)
time frame: 3 years
description: The DMFS is evaluated and calculated from the date of random assignment until the day of first distant metastases or until the date of the last follow-up visit.
measure: Overall response rate
time frame: 16 weeks after completion of IMRT
description: Tumour response was classified according to RECIST, version 1.1
measure: Incidence of acute and late toxicity
time frame: 3 years
description: Incidence of acute toxicity is calculated for each adverse event respectively and severity is evaluated on basis of Common Terminology Criteria for Adverse Events (CTCAE) 4.0 criteria.Late radiation toxicities were assessed using the Radiation Therapy Oncology Group and European Organization for Research and Treatment of Cancer late radiation morbidity scoring scheme.
arm group label: TPF+CCRT
arm group type: Experimental
description: Patients receive induction chemotherapy with paclitaxel liposome (135mg/m2 on day 1) ,cisplatin (25mg/m2 on day 1-3) and 5-fluorouracil (750mg/m2 civ 120h) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg/m2) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) .
arm group label: CCRT+ PF
arm group type: Active Comparator
description: Patients receive concurrent IMRT and cisplatin (100mg/m2) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) , then followed by three cycles of adjuvant chemotherapy with cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every four weeks for three cycles four weeks after radiotherapy.
intervention type: Drug
intervention name: TPF+CCRT
description: Patients receive paclitaxel liposome (135mg/m2 on day 1) , cisplatin (25mg/m2 on day 1-3) and 5-fluorouracil (750mg/m2 civ 120h) every three weeks for three cycles of induction chemotherapy before radiotherapy.
Patients receive IMRT and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy (D1,D22,D43 of RT)
arm group label: TPF+CCRT
other name: TPF induction chemotherapy
intervention type: Drug
intervention name: CCRT+ PF
description: Patients receive cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every four weeks for three cycles 4 weeks after radiotherapy.
Patients receive IMRT and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy (D1,D22,D43 of RT)
arm group label: CCRT+ PF
other name: Adjuvant PF
criteria: 
gender: All
minimum age: 18 Years
maximum age: 65 Years
healthy volunteers: No
last name: Hai-Qiang Mai, MD,PhD
role: Study Chair
affiliation: Sun Yat-sen Universitty Cancer Center
facility: 
country: China
citation: Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998 Apr;16(4):1310-7. doi: 10.1200/JCO.1998.16.4.1310.
PMID: 9552031
citation: Lee AW, Tung SY, Ngan RK, Chappell R, Chua DT, Lu TX, Siu L, Tan T, Chan LK, Ng WT, Leung TW, Fu YT, Au GK, Zhao C, O'Sullivan B, Tan EH, Lau WH. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials. Eur J Cancer. 2011 Mar;47(5):656-66. doi: 10.1016/j.ejca.2010.10.026. Epub 2010 Nov 26.
PMID: 21112774
citation: Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, Chan AT, Huang PY, Benhamou E, Zhu G, Chua DT, Chen Y, Mai HQ, Kwong DL, Cheah SL, Moon J, Tung Y, Chi KH, Fountzilas G, Zhang L, Hui EP, Lu TX, Bourhis J, Pignon JP; MAC-NPC Collaborative Group. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015 Jun;16(6):645-55. doi: 10.1016/S1470-2045(15)70126-9. Epub 2015 May 6.
PMID: 25957714
citation: Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, Chen XZ, Li JG, Zhu XD, Hu CS, Xu XY, Chen YY, Hu WH, Guo L, Mo HY, Chen L, Mao YP, Sun R, Ai P, Liang SB, Long GX, Zheng BM, Feng XL, Gong XC, Li L, Shen CY, Xu JY, Guo Y, Chen YM, Zhang F, Lin L, Tang LL, Liu MZ, Ma J. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016 Nov;17(11):1509-1520. doi: 10.1016/S1470-2045(16)30410-7. Epub 2016 Sep 27.
PMID: 27686945
citation: Chen C, Wang FH, An X, Luo HY, Wang ZQ, Liang Y, Zhang L, Li YH. Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma. Cancer Chemother Pharmacol. 2013 Feb;71(2):371-8. doi: 10.1007/s00280-012-2020-x. Epub 2012 Nov 10.
PMID: 23143190
responsible party type: Principal Investigator
investigator affiliation: Sun Yat-sen University
investigator full name: Hai-Qiang Mai,MD,PhD
investigator title: Professor
mesh term: Carcinoma
mesh term: Nasopharyngeal Carcinoma
sharing ipd: Undecided